期刊文献+

葡萄球菌中毒性休克毒素的分离纯化及其体外抗肝癌活性分析 被引量:2

Purification and in vitro Anti-hepatocellular Carcinoma Activity of Toxic Shock Syndrome Toxin-1
下载PDF
导出
摘要 采用固体膜进行TSST 1的产毒培养,然后从金葡菌产毒产物中经CM纤维素离子交换层析、SephadexG 75、SephacrylS 200三步纯化,成功地获得了纯度为95.3%的毒素,SDS PAGE呈现单一条带,与其对应抗血清有免疫学特异反应,不含核酸、糖和其它肠毒素等物质.与同类方法相比,该方法步骤少、快速、简便.对其体外抗肝癌活性进行了分析,首次证明即使TSST 1的浓度为10-8g L仍然对人肝癌细胞有显著抑制作用. A simple and efficient three step procedure was developed to purify TSST1 after culturing the toxinproducing bacteria on membrane.The purification procedure involved ionexchange chromatography on CM cellulose,gel filtration on Sephadex G75 and Sephacryl S200.TSST1 with high purity was obtained.The purified toxin is a simple protein with a molecular weight of 22 kD as determined by SDSPAGE.Other material such as nuclear acid and staphylococcal enterotoxins are not contained in the purified products.Specific reaction of purified TSST1 is demonstrated by immunodiffusion test.Our improved purification procedure is simple, more rapid and convenient than previously reported methods.The antitumor activity of TSST1 was also analysed.It was demonstrated for the first time that even 10-8?g/L TSST1 can notably inhibit the tumor growth of human hepatocellular carcinoma in vitro.
出处 《生命科学研究》 CAS CSCD 2002年第4期347-350,共4页 Life Science Research
基金 国家自然科学基金资助(30171091)
关键词 葡萄球菌中毒性休克毒素 分离纯化 体外抗肝癌活性 肝细胞癌 TSST-1 purification hepatocellular carcinoma
  • 相关文献

参考文献6

  • 1雷祚荣.葡萄球菌毒素和葡萄球菌毒素病[M].北京:中国科技出版社,1993:1~9.
  • 2张京泰,张金成.超级抗原治疗肿瘤的最新进展[J].海南医学,2000,11(1):44-45. 被引量:9
  • 3TERMAN. Tumor killing effects of enterotoxins, superantigens, and related compounds[P]. United States Patent 6,221,351,2001.
  • 4雷祚荣 曲丽云 王鲁明.等金葡菌C1、C2型肠毒素的提纯和某些理化性质的鉴定[J].微生物学通报,1986,:13-116,113.
  • 5DOHLSTEN M, SUNDSTEDT A, BJORKLUND M, et al. Superantigen-induced cytokines suppress growth of human colon-carcinoma cells[J]. Int J Cancer, 1993,54,482-488.
  • 6姜永强.超抗原与肿瘤生物治疗[J].国外医学(肿瘤学分册),1996,23(5):257-260. 被引量:17

二级参考文献23

  • 1Kalland T, Dohlsten M, Lind P, et al Monoclonal antibodies and superantigens: a novel therapeutic approach. Mcd Oncol Tumor Pharmacother, 1993, 10(1-2): 37
  • 2Lando PA, Dohlsten M, Hedlund G, et al. T cellkilling of human colon carcinomas by monoclonal-antibody- targeted superantigens. Cancer Immunol Immunother, 1993, 36 (4): 223
  • 3Dohlsten M, Sundstedt A, Bjorklund M, et al. Superantigen - induced cytokincs suppress growth of human colon-carcioma cellss. Int J Caner, 1993, 54 (3)482
  • 4Ochi A, Migita K, Xu J, et al. In vivo tumor immunotherapy by a bacterial superantigen. J Immunol,1993, 151 (6): 3180
  • 5Shu S, Krinock RA, Matsumura T, et al. Stimulation of tumor- draining lymph onde cells with superantigenic staphylococcal toxins leads to the generation of turnor- specific effector T cells. J Immunol, 1994,152 (3): 1277
  • 6Belfrage H, Bhiladvala P, Hedlund G, et a1. Combined activation of murine lymphocytes with staphylococcal cnterotoxin and interleukin - 2 results in additive cytotoxic activity. Cancer Immunol Immunother,1994, 38 (4): 265
  • 7Norrby- Teglund A, Norgren M, Holm SE, et al.Similar cytokine induction profiles of a movel streptococcal cxotoxin, MF, and pyrogenic exotoxins A and B. Infect Immun, 1994, 62 (9): 3731
  • 8Dohlsten M, Abrahmsen L, Bjork P, Monoclonal antibody- superantigen fusion proteins: tumor- specific agents for T - cell - based tumor therapy. Proc Natl Acad Sci USA, 1994, 91 (19): 8945
  • 9Ihlc J, Holzer U, Krull F, et al. Antibody - targeted superantigens induce 1ysis of major histocornpatibility complex class Ⅱ - negative T - cell leukemia lines. Cancer Res 1995, 55 (3): 623
  • 10Belfrage H, Dohlsten M, Hedlund G, et al. Enhanced and prolonged effcacy of superantigen - in-duced cytotoxic T lymphocyte activity by interleukin-2 in vivo. Cancer Immunol Immunother, 1995,41 (2): 87

共引文献25

同被引文献21

  • 1刘明华,张庆玲,刘玉馥,府伟灵.创伤患者金黄色葡萄球菌感染的分子流行病学研究[J].中华医院感染学杂志,2004,14(1):100-103. 被引量:11
  • 2姚咏明,盛志勇.金黄色葡萄球菌外毒素与脓毒症及多器官损害[J].中华创伤杂志,2004,20(12):711-714. 被引量:18
  • 3Powell C,Bubb S,Clark J. Toxic shock syndrome in a neonatePediatr Infect Dis J,2007,26(8) :759-760.
  • 4Hertzer CM. Toxic shock syndrome: broadening the differential diagnosis. J Am Board Faro Pract,2001,14(2) : 131-136.
  • 5Parsonnet J, Hansmann MA, Delaney ML, et al. Prevalence of toxic shock syndrome toxin 1-producing Staphylococcus aureus and the presence of antibodies to this superantigen in menstruating women.J Clin Microbiol, 2005,43(9) :4628-4634.
  • 6Durand G, Bes M, Meugnier H, et al. Detection of new methicillin-resistant Staphylocoocus aureus clones containing the toxic shock syndrome toxin 1 gene responsible for hospital- and community-acquired infections in France.J Clin Microbiol,2006,44(3):847-853.
  • 7Nakngawa S, Kushiya K, Taneike I, et al. Specific inhibitory action of anisodamine against a staphylococcal superantigenic toxin, toxic shock syndrome toxin 1 ('ISST-1),leading to down-regulation of cytokine production and blocking of TSST-1 toxicity in mice. Clin Diagn Lab Immunol,2005,12(3) :399-408.
  • 8Alouf JE, Muller-Alouf H. Staphylococcal and streptococcal superantigens:molecular, biological and clinical aspects. Int J Med Microbiol, 2003,292(7-8) : 429-440.
  • 9Baker MD, Acharya KR. Superantigens: structure-function relationships. Int J Med Microbiol,2004,293(7-8):529-537.
  • 10Kreiswirth BN,Lofdahl S, Betley MJ, et al.The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. Nature, 1983,305(5936) :709-712.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部